Look at this website as a comprehensive source of information about dolutegravir for healthcare professionals in Belgium and Luxembourg.
You are now leaving the dolutegravir.com site
Thank you for choosing to report an adverse event.
For Belgium: Please report adverse events to the Belgian Centre for Pharmacovigilance for medicines for Human use (BCPH) of the Federal Agency for Medicines and Health Products (FAMHP) on the following address: email@example.com or via the ‘yellow card’ available on the website http://www.fagg-afmps.be or to ViiV Healthcare SPRL/BVBA at the number +32 10 85 65 00.
For Luxembourg: Please report adverse events to the Minister of Health of Grand-Duché of Luxembourg (Pharmacy and Drug Division, at fax number +35 2 24795615 or by post) or at Regional Pharmacovigilance Centre of Lorraine (at fax number +33 3 83 32 33 44 or at firstname.lastname@example.org) or to ViiV Healthcare SPRL/BVBA at the number +32 10 85 65 00.